1 / 26

Risk of Myocardial Infarction on NSAIDs Study

Study analyzing MI risk in patients on Cox-2 & traditional NSAIDs, using QRESEARCH data. Includes aims, design, results, limitations, and implications.

miguelcrow
Download Presentation

Risk of Myocardial Infarction on NSAIDs Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Risk of myocardial infarction on Cox 2 & conventional NSAIDs Julia Hippisley-Cox Carol Coupland

  2. Goals of presentation • Overall • Present analysis of study examining risk of MI in patients on NSAIDS • Initially • Overview of data source (QRESEARCH) used for the project to set context

  3. Acknowledgements • Co-author • Carol Coupland • QRESEARCH team • Mike Pringle • Mike Heaps • Justin Fenty • Gavin Langford • David Stables • EMIS and EMIS practices

  4. QRESEARCH:What is it? • Patient level consolidated database • Anonmyised data • Longitudinal data for 15+ years • Derived from GP clinical records • Validated against external and internal measures • Industry independent

  5. QRESEARCH:UK coverage • Largest database in the world • 488 UK practices • > 6 practices in every Strategic Health Authority (administrative area) • > 8 million patients including those who died, left and still registered • > 29 million person years observation

  6. QRESEARCH:Data contents • Socio-demographics • Diagnoses • Clinical values • Laboratory tests • Prescription data • Consultation data • Category of clinician entering data

  7. Study aims • To determine risk of Myocardial Infarction in patients taking • use Cox 2 inhibitors • traditional NSAIDS • Compared with non use

  8. Background • Cox 2 drugs • Type of painkiller • Supposed to cause less gastrointestinal problems than traditional NSAIDS • But original RCT compared rofecoxib with naproxen • Found 5 fold increased risk of MI • Adverse effect of Rofecoxib • Beneficial effect of naproxen

  9. Study design & setting • Nested case control study • 367 UK practices contributing to the new UK QRESEARCH • Registered population > 3 million patients [6% UK population] • Study period Aug 2000-July 2004

  10. Study cohort • All patients aged 25-100 • Registered with practices from 1st Aug 2000 to 31st July 2004 • Prior registration >12 months • > 8 million person years observation • 9218 patients with a first MI

  11. Case & controls • CASES • 1st ever MI during 4 year study period • CONTROLS • 10 controls matched by • age • Sex • Practice • Calendar year • Cases & controls all with 3 years + prior data

  12. Exposure • Main exposure • Use of any NSAID in 3 years prior to index date • Extracted • Type • Date • Count of prescription

  13. Types of NSAIDS • Overall 27 various NSAIDS • Groups for analysis • Celecoxib • Rofecoxib • Other Cox2 • Diclofenac • Ibuprofen • Naproxen • Other NSAIDs

  14. Confounders • Ischaemic heart disease • Diabetes • Hypertension • OA • Rheumatoid arthritis • Smoking • Obesity • Deprivation • Aspirin • Statins • Antidepressants

  15. Statistical analysis • Conditional logistic regression • Odds ratios + 95% CI • Unadjusted & adjusted • Investigations for interactions

  16. Results: baseline • Cases & controls well matched for • Age, sex, time, practice • Cases had higher prevalence • Smoking • Obesity • Deprivation • comorbidity

  17. Increased risk of MI (95% CI) • Increased risk of MI current use of • Rofecoxib 30% increase (10%-60%) • Other Cox 2 27% increase (0%-60%) • Diclofenac 55% increase (40%-70%) • Ibuprofen 20% increase (10%-40%) • V significant duration response • More scripts causing higher risk

  18. Numbers needed to harm (aged 25 plus) • No. patients treated for one year for one additional MI to result • Diclofenac 1066 (95% CI 815 -1504) • Rofecoxib 1833 (955% CI 961-6517) • ibuprofen 2444 (95% CI 1504-5332)

  19. Numbers needed to harm(patients 65 plus) • No. patients 65 + treated for one year for one additional MI to result • Diclofenac 521 (95% CI 355 to 866) • Rofecoxib 695 (95% CI 344 to 3841) • Ibuprofen 1005 (95% CI 569 to 3089)

  20. Interactions, age, naproxen • No convincing interactions • Aspirin & NSAIDS • CHD and any NSAID • So risk applies despite presence of these • No evidence that Naproxen lowers risk MI

  21. Limitations study • Observational study • Subject to bias • Misclassification • Recording bias • Confounding by indication • But likely to have applied to all NSAIDS • Residual confounding

  22. Overcoming confoundingby indication • To address confounding by indication restricted analysis to those without • Diabetes • Ischaemic heart disease • Also restricted analysis aged > 65 years • This did not change results

  23. Setting it in context • Since this work was completed • Rofecoxib withdrawn • Valdecoxib withdrawn • Celecoxib risk • FDA memo on web • Suggests class effect not just Cox 2 but also NSAIDs but serious lack of placebo controlled safety data

  24. However • Observational studies cannot prove anything • They are subject to residual confounding • They can only raise concerns • Sometimes observational studies are wrong eg HRT • Rapid access to very large representative samples & potential • Can help evaluate risks & benefits outside RCT setting

  25. Conclusions • Our study suggests risk of MI is a class effect as conventional NSAIDs also seem to increase risk • FDA memo also suggests this • ? Time to evaluate cardiovascular safety all NSAIDs

More Related